December 24, 2024
Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action
Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.
Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment
AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment
AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment
Bluenote Secures $10M Funding to Revolutionize Life Sciences Regulatory Workflows with Generative AI
Bluenote, Generative AI, Life Sciences, Regulatory Workflows, Funding, Lux Capital, Elad Gil
Sanofi and SK Bioscience Enhance Partnership for Next-Generation Pneumococcal Conjugate Vaccines
Sanofi, SK Bioscience, Pneumococcal Conjugate Vaccines (PCVs), Next-Generation Vaccines, Pediatric and Adult Populations, Phase III Testing, PCV21
FDA Imposes Import Restrictions on 11 Viatris Products from Indian Facility Due to Regulatory Violations
Viatris, FDA, Import Restrictions, India Facility, Regulatory Violations, Pharmaceutical Manufacturing
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
Zepbound, FDA approval, obstructive sleep apnea, obesity, tirzepatide, sleep disorder treatment
Sotyktu Expands Potential with Successful Phase III Trials in Psoriatic Arthritis
Sotyktu, deucravacitinib, psoriatic arthritis, Phase III trials, Bristol Myers Squibb, TYK2 inhibitor